Haemonetics
HAE
#3434
Rank
NZ$6.94 B
Marketcap
NZ$144.16
Share price
-0.87%
Change (1 day)
1.49%
Change (1 year)

P/E ratio for Haemonetics (HAE)

P/E ratio as of December 2025 (TTM): 24.1

According to Haemonetics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.0918. At the end of 2024 the company had a P/E ratio of 30.4.

P/E ratio history for Haemonetics from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202430.4-10.85%
202334.2-18.7%
202242.0-65.71%
2021123
2018112-165.46%
2017-171-234.9%
2016127-486.28%
2015-32.8-150.98%
201464.311.03%
201357.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Thermo Fisher Scientific
TMO
32.7 35.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Stryker Corporation
SYK
45.6 89.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Becton Dickinson
BDX
34.1 41.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Cerus
CERS
-23.3-196.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
-27.6-214.37%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-37.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.3-19.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Medtronic
MDT
27.9 15.88%๐Ÿ‡ฎ๐Ÿ‡ช Ireland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.